18F-2-fluoro-2-deoxy-D-glucose positron emission tomography in staging of locally advanced breast cancer

Journal of Clinical Oncology

Volumn 22, Issue 7, 2004, Pages 1253-1259

  Van Der Hoeven, Jacobus J M ^a   Krak, Nanda C ^a   Hoekstra, Otto S ^a   Comans, Emile F I ^a   Boom, Robert P A ^a   Van Geldere, Dick ^a   Meijer, Sybren ^a   Van Der Wall, Elsken ^a   Buter, Jan ^a   Pinedo, Herbert M ^a   Teule, Gerrit J J ^a   Lammertsma, Adriaan A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ARTICLE; BONE SCINTISCANNING; BREAST CANCER; CANCER LOCALIZATION; CANCER SCREENING; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SARCOIDOSIS; THORAX RADIOGRAPHY; ULTRASOUND; ADENOCARCINOMA; ADULT; BREAST TUMOR; COMPUTER ASSISTED EMISSION TOMOGRAPHY; LABORATORY DIAGNOSIS; LUNG CARCINOMA; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; PROSPECTIVE STUDY; RADIOGRAPHY; SCINTISCANNING;

ADENOCARCINOMA; ADULT; BREAST NEOPLASMS; CARCINOMA, DUCTAL; CARCINOMA, LOBULAR; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 2142762454     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.07.058     Document Type: Article

References (33)

1. Perez EA, Foo ML, Fulmer JT: Management of locally advanced breast cancer. Oncology 11:9-17, 1997 (suppl 9)
2. Wahl RL, Cody RL, Hutchins GD, et al: Primary and metastatic breast carcinoma: Initial clinical evaluation with PET with the radiolabeled glucose analogue 2-F-18-fluoro-2-deoxy-D-glucose. Radiology 179:765-770, 1991
3. Tse NY, Hoh CK, Hawkins RA, et al: The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. Ann Surg 216:27-34, 1992
4. Adler LP, Crowe JP, al-Kaisi NK, et al: Evaluation of breast masses and axillary lymph nodes with F-18-2-deoxy-2-fluoro-D-glucose PET. Radiology 187:743-750, 1993
5. Nieweg OE, Kim EE, Wong WH, et al: Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer 71:3920-3925, 1993
6. Bruce DM, Evans NT, Heys SD, et al: Positron emission tomography: 2-deoxy-2-18F-fluoro-D-glucose uptake in locally advanced breast cancers. Eur J Surg Oncol 21:280-283, 1995
7. Scheidhauer K, Scharl A, Pietrzyk U, et al: Qualitative F-18 FDG positron emission tomography in primary breast cancer: Clinical relevance and practicability. Eur J Nucl Med 23:618-623. 1996
8. Palmedo H, Bender H, Grunwald F, et al: Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and technetium-99m methoxyisobutylisonitrile scintimammography in the detection of breast tumors. Eur J Nucl Med 24:1138-1145, 1997
9. Avril N, Rose CA, Schelling M, et al: Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: Use and limitations. J Clin Oncol 18:3495-3502, 2000
10. Oshida M, Uno K, Suzuki M, et al: Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[f- 18]-D-glucose. Cancer 82:2227-2234, 1998
11. Bos R, van der Hoeven JJ, van der Wall E, et al: Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 20:379-387, 2002
12. Utech CI, Young CS, Winter PF: Prospective evaluation of fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry. Eur J Nucl Med 23:1588-1593, 1996
13. Adler LP, Faulhaber PF, Schnur KC, et al: Axillary lymph node metastases: Screening with F-18-2-deoxy-2-fluoro-D-glucose (FDG)PET. Radiology 203:323-327, 1997
14. Smith IC, Ogston KN, Whitford P, et al: Staging of the axilla in breast cancer: Accurate in vivo assessment using positron emission tomography with 2-flurine-18-fluoro-2-deoxy-D-glucose. Ann Surg 228:220-227, 1998
15. Schirrmeister H, Kühn T, Guhlmann A, et al: Fluorine-18 2-deoxyglucose-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: Comparison with the standard staging procedures. Eur J Nucl Med 28:351-358, 2001
16. Greco M, Crippa F, Agresti R, et al: Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: Clinical evaluation and alternative management. J Natl Cancer Inst 93:630-635, 2001
17. Torrenga H, Licht J, Van der Hoeven JJM, et al: Re: Axillary lymph node staging in breast cancer by 2-Fluoro-2-deoxy-D-glucose positron emission tomography-Clinical evaluation and alternative management. J Natl Cancer Inst 93:1659-1661, 2001
18. Van der Hoeven JJ, Hoekstra OS, Comans EF, et al: Determinants of diagnostic performance of F-18 fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer. Ann Surg 236:619-624, 2002
19. Bender H, Kirst J, Palmedo H, et al: Value of 18-fluorodexyglucose positron emission tomography in the staging of recurrent breast cancer. Anticancer Res 17:1687-1692, 1997
20. Dose J, Bleckmann C, Bachmann S, et al: Comparison of fluorodeoxyglucose positron emission tomography and "conventional diagnostic procedures" for the detection of distant metastases in breast cancer patients. Nucl Med Commun 23:857-864, 2002
21. Cook GJ, Houston S, Rubens R, et al: Detection of bone metastases in breast cancer by F-18 FDG PET: Differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 16:3375-3379, 1998
22. Lonneux M, Borbarth I, Berlière M, et al: The place of whole body PET FDG for the diagnosis of distant recurrence of breast cancer. Clin Positron Imaging 3:45-49, 2000
23. Veronesi U, Marubini E, Del Vecchio M, et al: Local recurrence and distant metastases after conservative breast cancer treatments: Partly independent events. J Natl Cancer Inst 87:19-27, 1995
24. Pinedo HM, Buter J, Luykx-de Bakker SA, et al: Extended neoadjuvant chemotherapy in locally advanced breast cancer combined with GM-CSF: Effect on tumour-draining lymph node dendritic cells. Eur J Cancer 39:1061-1067, 2003
25. Stadmauer EA, O'Neil A, Goldstein LJ, et al: Conventional chemotherapy compared with high-dose chemotherapy plus autologous stem cell transplantation for metastatic breast cancer. N Engl J Med 342:1069-1076, 2000
26. Lotz JP, Cure H, Janvier M, et al: Intensive chemotherapy and autograft of hematopoietic stem cells in the treatment of metastatic cancer: Results of the national protocol Pegase 04. Hematol Cell Ther 41:71-74, 1999
27. Lotz JP, Curé H, Janvier M, et al: High dose chemotherapy (HD-CT) with hematopoietic stem cell transplantation (HSCT) for metastatic breast cancer (MBC): Results of the French protocol PEGASE 04. Proc Am Soc Clin Oncol 18:43a, 1999 (abstr 161)
28. Berry DA, Broadwater G, Klein JP, et al: High-dose versus standard chemotherapy in metastatic breast cancer: Comparison of Cancer and Leukemia Group B trial with data from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 20:743-750, 2002
29. Yap CS, Seltzer MA, Schiepers C, et al: Impact of whole-body 18F-FDG PET on staging and managing patients with breast cancer: The referring physician's perspective. J Nucl Med 42:1334-1337, 2001
30. Lardinois D, Weder W, Many TF, et al: Staging of non-small cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 348:2500-2507, 2003
31. Torizuka T, Zasadny KR, Recker B, et al: Untreated primary lung and breast cancers: Correlation between F-18 FDG kinetic rate constants and findings of in vitro studies. Radiology 207:767-774, 1998
32. Smith IC, Welch E, Hutcheon W, et al: Positron emission tomography using 18-F-Fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 18:1676-1688, 2000
33. Schelling M, Avril N, Nahrig J, et al: Positron emission tomography using 18F fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 18:1689-1695, 2000